Supplementary Materials

Supplementary Material for:

Systems Pharmacology of Adverse Event Mitigation by Drug Combinations

Shan Zhao, Tomohiro Nishimura, Yibang Chen, Evren U. Azeloglu, Omri Gottesman, Chiara Giannarelli, Mohammad U. Zafar, Ludovic Benard, Juan J. Badimon, Roger J. Hajjar, Joseph Goldfarb, Ravi Iyengar*

*Corresponding author. E-mail: ravi.iyengar@mssm.edu

Published 9 October 2013, Sci. Transl. Med. 5, 206ra140 (2013)
DOI: 10.1126/scitranslmed.3006548

This PDF file includes:

  • Methods
    Fig. S1. MI reports as a function of the quarter they were filed in FAERS and the age of the patient.
  • Fig. S2. Schematic of how the two hypotheses for potential mechanisms of rosiglitazone-induced MI was evaluated.
  • Fig. S3. Fluid retention network downstream of rosiglitazone.
  • Table S1. Additional drugs modulating rosiglitazone-associated MI adverse events from FAERS.
  • Table S2. Factoring by gender of MI % in patients on rosiglitazone with and without exenatide.
  • Table S3. Factoring by occupation of the person filing the FAERS report of MI % in patients on rosiglitazone with and without exenatide.
  • Table S4. Comparison of MI % between patients on rosiglitazone and metformin patients, with and without exenatide.
  • Table S5. Type 2 diabetic indications that are documented in FAERS using terms specified in the MeDRA.
  • Table S6. Reduction of MI for patients with type 2 diabetes treated with and without rosiglitazone.
  • Table S7. Percent usage of third drug along with exenatide usage for patients on rosiglitazone.
  • Table S8. Exenatide effect after factoring for third drugs (table S7) associated with exenatide usage on patients treated with rosiglitazone.
  • Table S9. Other adverse events associated with exenatide usage in rosiglitazonetreated patients.
  • Table S10. Exenatide effect after factoring for non–MI-related adverse events (table S9) associated with exenatide usage in rosiglitazone-treated patients.
  • Table S11. Logistic regression of possible covariates for the outcome of MI, including the use of exenatide as a factor.
  • Table S12. Logistic regression of possible covariates for the outcome of MI, excluding the usage of exenatide as a factor.
  • Table S13. Effect of rosiglitazone on MI before and after Q2 2007 publication of (11), which describes MI risks associated with rosiglitazone.
  • Table S14 legend

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • File “table S14.xlsx” (Exhaustive list of drug B mitigation of drug A–associated adverse events in FAERS)
  • File “CodeFiles.pdf” (computer code for analysis of FAERS)

[Table S14 and Code Files]